Best Clinical Labs IT Companies in New York, United States
The 44 best Clinical Labs IT companies in New York, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: AIdoc.
Ranked: Best Clinical Labs IT companies in New York
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 10BioSystems 10BioSystems provides scientific software products, technology consulting and strategic solutions for the… | — | — | — | Sebastian Jayaraj Founder | — | Deadpooled | — | — |
| 2 | aycan Vendor-neutral medical imaging solutions improving workflow efficiency and patient care | — | — | 7 | Frank Burkhardt CEO & MD | — | Acquired | — | — |
| 3 | Bodyquant Medical imaging and diagnostics company | — | — | — | Mark Punyanitya Co-Founder & CEO | — | Deadpooled | — | — |
| 4 | Care to Care Provider of multi speciality benefits management solutions | — | — | 46 | — | — | Funding Raised | — | — |
| 5 | Colonai AI-based disease diagnosis tool for gastroenterologists | — | — | 4 | Bina Bansinath Co-Founder | — | Funding Raised | — | — |
| 6 | DragonflyPHD Online patient report management tool for pharmacies and clinics | — | — | — | Julie Eskay Eagle Founder & CEO | — | Unfunded | — | — |
| 7 | HEALTHePRACTICES Cloud-based teleconsultation platform for providers | — | — | 1 | — | — | Unfunded | — | — |
| 8 | Imaging On Call Teleradiology service provider | — | — | — | Robert Rodriguez Founder | — | Acqui-Hired | — | — |
Top 12 Clinical Labs IT companies in New York
#1
Series E · New York City, New York · founded 2016 · 403 employees$274.5Mraised▾
Developer of clinical AI solutions for healthcare imaging and patient management. The company offers a platform designed for seamless integration into existing IT infrastructure. It provides tools for care coordination, patient identification, and systems integrations. The company focuses on streamlining workflows and centralizing patient management across various medical specialties.
- Apr 2026Series E$150M
- Jul 2025Series E$110M
- Jul 2025Conventional Debt$40M
- Nov 2023Series D$30M
#2
Series B · New York City, New York · founded 2019 · 12 employees$31.5Mraised▾
Provider of an AI-based medical image analysis software for healthcare professionals. The software has AI-enabled tools that assist professionals to diagnose pathological samples for diagnosis and treatment solutions. The tool uses AI technology to analyze pathological images of the patient and predict disease, it assists in the enhancement of the image and provides workflow management solutions.
- May 2025Series B$11.2M
- Feb 2024Series B$20.7M
#3
Funding Raised · New York City, New York · founded 2015 · 7 employees$5Mraised▾
Provider of pathological image analysis and diagnosis device for clinicians. The company has developed a digital diagnostic imaging platform that acts as a diagnostic tool for the analysis of 3D digital pathology images. The system has features to analyze surgically-removed tissue specimens, histopathology specimens, and more at the point of care.
- Jul 2025Grant (prize money)$2.2M
- Jan 2022Grant (prize money)$276K
- Mar 2021Grant (prize money)$492.5K
- Aug 2019Grant (prize money)$2M
#4
Acquired · New York City, New York · founded 2018 · 133 employees$239.5Mraised▾
Developer of AI applications and foundation models for cancer diagnostics. The company provides tissue-based AI-assisted applications to support cancer detection, subtyping, and molecular biomarker discovery. It offers technology to accelerate research and development of computational pathology applications. The company’s co-pilot is designed to streamline pathology workflows and unlock precision medicine.
- Jan 2023Series C$19.5M
- Mar 2021Series C$25M
- Jan 2021Series C$100M
- Jul 2020Series B$20M
#5
Series B · New York, New York · founded 2012 · 20 employees$15.9Mraised▾
Provider of artificial intelligence-based ultrasound to diagnose cancer. The company has developed cancer diagnosis software using AI on breast ultrasound images. It is used to classify suspicious lesions and aligning to a BI-RADS category.
- May 2024Conventional Debt$130M
- Feb 2023Series B$8M
- Aug 2022Series A$2.6M
- Jan 2021Series A$280K
#6
Series B · Morrisonville, New York · founded 2002 · 20 employees$30.9Mraised▾
Provider of MRI-based diagnostic software for cardiac disease. It has developed three products SENC calculates cardiac strain in a single heartbeat, eliminating the need to hold the breath, HARP is an FDA-cleared software that automatically analyzes tagged MRI images and measures cardiac function and VIRTUE provides a suite of tools to view and analyze cardiac images.
- Jun 2023Series B$2.7M
- Mar 2021Series B$11.2M
- Mar 2019Series A$7M
- Jul 2017Series A$5M
#7
Seed · Brooklyn, New York · founded 2011$1Mraised▾
Provider of MRI image enhancement software. This software suite enhances diffusion and functional MRI image quality using a patented MP-PCA algorithm. It leverages redundancy in MRI measurements to reduce noise and includes modules supporting weighted linear least squares and Bayesian fitting for quantitative analysis of diffusion-weighted imaging. The software also features DICOM data routing for seamless integration into medical workflows. The technology improves image quality, allowing for higher resolution and fewer images needed, ultimately benefiting both providers and patients.
- Jan 2025Grant (prize money)$455K
- Aug 2023Seed$590K
- 2023Seed—
#8
Acquired · New York City, New York · founded 2006 · 146 employees$47.8Mraised▾
Ambra Health gives care providers and patients the ability to access, manage, and store medical imaging data online. Their DG Suite product enables organizations to deploy applications for medical imaging collaboration and image data management. It provides features such as enterprise image exchange, PACS, vendor-neutral archive, web viewer, workflow & analytics, etc.
- Nov 2017Series A$7.4M
- Sep 2016Series A$6M
- Mar 2016Series A$6M
- Nov 2015Venture Debt$3M
#9
Acquired · Suffern, New York · founded 1997 · 146 employees$16Mraised▾
Provider of AI-based platform to detect precancerous tissues. The company uses proprietary platform technology WATS3d Biopsy to detect precancerous changes. The products of the company include OralCDx a non-invasive oral brush biopsy and EndoCDx a transepithelial laryngeal brush biopsy.
- Jun 2020Series A$5M
- Dec 2019Series A$11M
#10
Series A · New York City, New York · founded 2016 · 10 employees$4Mraised▾
AI-powered radiology reporting and annotation platform for medical imaging. They accelerate medical imaging AI development and deployment with DICOM-native data annotation tools. The platform supercharges reporting workflows with AI, unlocking efficiency and productivity. It offers features like automatic template selection, key findings dictation mapping, impression generation, and automated billing code generation. The platform improves patient communication with patient-friendly audio messages. It supports HL7/DICOM integration, multi-device sync, multilingual support, and contextual AI chat. The platform enables doctors to create high-quality labeled datasets, deploy models, and build AI-driven clinical workflows with native DICOM support, FDA-cleared viewer, AI-assisted annotation, and developer APIs. This is a B2B SaaS platform that leverages Artificial Intelligence to improve healthcare outcomes.
- Mar 2022Series A$4M
#11
Acquired · Rochester, New York · founded 2000 · 91 employees$3.8Mraised▾
Provider of imaging-based clinical trial solutions. The company uses a collaborative approach to optimize imaging solutions, and provide quantitative imaging data that help detect disease progression faster and identify therapeutic benefits sooner. Claim to deliver highly reproducible imaging analysis. Key therapeutic areas served include Oncology, Hematology, Muscular Disease, Metabolic Disorders, and Neuroscience across imaging modalities like CT, MRI, MRE, DXA, X-ray, PET, and Ultrasound.
- Apr 2012Post IPO$3M
- Sep 2009Grant (prize money)$224.1K
- Sep 2009Grant (prize money)$224.1K
- 2007Post IPO$4.3M
#12
Funding Raised · New York City, New York · founded 2011$769Kraised▾
Quantitative susceptibility mapping tool. It supports image acquisition, reconstruction, and 3 D visualization. QSM enables the investigation of tissue magnetic susceptibility using magnetic resonance imaging and is useful for the identification and quantification of specific biomarkers including iron, calcium, gadolinium, and superparamagnetic iron oxide (SPIO) nanoparticles. It can be used for diagnosis study of Intracerebral Hemorrhage, Intracranial calcification, Neurodegenerative Diseases, and for contrast agent quantification.
- Jul 2021Grant (prize money)$255.6K
- Sep 2012Grant (prize money)$168.7K
- Sep 2011Grant (prize money)$172.4K
- Aug 2011Grant (prize money)$172.4K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Clinical Labs IT coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.